Kristin Hammer

Title: Kristin Hammer: Innovator in Histone Deacetylase Inhibition

Introduction

Kristin Hammer is a prominent inventor based in Sollentuna, Sweden. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit histone deacetylase activity. With a total of five patents to her name, her work has implications for various therapeutic areas.

Latest Patents

Among her latest patents, Kristin has developed bicyclic hydroxamic acids that serve as inhibitors of mammalian histone deacetylase activity. These compounds are useful in therapy for treating autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders. Another notable patent involves benzimidazole derivatives, which are also designed as inhibitors of mammalian histone deacetylase activity. These compounds are particularly relevant for treating disorders mediated by HDAC6, including autoimmune disorders and certain types of cancer.

Career Highlights

Throughout her career, Kristin has worked with notable companies such as Kancera AB and Biovitrum AB (publ). Her innovative research has positioned her as a key figure in the development of new therapeutic agents targeting histone deacetylases.

Collaborations

Kristin has collaborated with esteemed colleagues, including Rune Ringom and Erik Ringberg. These partnerships have further enhanced her research and development efforts in the field.

Conclusion

Kristin Hammer's contributions to the field of medicinal chemistry and her innovative patents highlight her role as a leading inventor. Her work continues to pave the way for new therapeutic options in the treatment of various disorders.